The 2023 data indicates that the Czech Republic leads the sale of Global Systemic Hormonal Preparations (excluding sex hormones and insulins) with $15.8 PPP per capita, followed by Luxembourg and the United Kingdom. The year-on-year variation highlights significant growth in South Korea at 9.39%, while Hungary experienced a decline of 2.3%. The data suggests stable markets in most countries, with Finland, Chile, and Portugal showing modest upward trends. Over the last five years, the regions have experienced varying CAGR, pointing to differing economic healthcare dynamics.
Future trends to watch include potential market expansions in South Korea due to strong sales growth and innovative hormonal therapies. The Czech Republic's sustained lead may face competition from countries improving their healthcare systems. Additionally, demographic shifts and technological advances could further influence systemic hormonal preparations' accessibility and demand across these regions.
Top countries in Systemic Hormonal Preparations Sales (Excluding Sex Hormones and Insulins) by Country
| # | 10 Countries | US Dollars PPP Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Czech Republic | 15.8 | 2023 | +2.6% | +0.65% | View data |
| 2 | 2 Luxembourg | 11.5 | 2023 | +0.88% | -0.51% | View data |
| 3 | 3 United Kingdom | 11.2 | 2023 | +1.82% | +2.92% | View data |
| 4 | 4 Finland | 10.9 | 2023 | +2.83% | +1.74% | View data |
| 5 | 5 Slovenia | 10.1 | 2023 | +2.02% | +0.81% | View data |
| 6 | 6 Switzerland | 9.7 | 2023 | +1.04% | +2.44% | View data |
| 7 | 7 Chile | 9.1 | 2023 | +3.41% | +1.61% | View data |
| 8 | 8 South Korea | 8.3 | 2023 | +3.75% | +9.39% | View data |
| 9 | 9 Estonia | 7.6 | 2023 | +4.11% | +3.5% | View data |
| 10 | 10 Hungary | 7.3 | 2023 | +1.39% | -2.3% | View data |
